Visualization of Carotid Atherosclerosis by 68Ga-MSA

K

Korea University

Status and phase

Completed
Phase 1

Conditions

Noninvasive Imaging of Atherosclerosis
Carotid Atherosclerosis
Atherosclerosis

Treatments

Other: 68Gallium-MSA

Study type

Interventional

Funder types

Other

Identifiers

NCT01893489
Ga_MSA_CAD_carotid

Details and patient eligibility

About

Until now, no specific atherosclerosis-targeting agent labeled with positron emitter is not yet available. Investigators developed neomannosyl human serum albumin(MSA) for the terminal mannose residues of MSA binding with the mannose receptors of macrophages in atherosclerosis, and investigators investigate whether 68Ga-MSA can be a novel agent for non-invasive molecular imaging of carotid atherosclerotic lesion in PET.

Enrollment

12 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

•coronary artery disease patients with carotid plaques

control without carotid plaque

Exclusion criteria

•pregnancy, allergy to albumin, any acute or chronic inflammatory disease, hematologic disease, liver disease, renal disease

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

12 participants in 2 patient groups

Atherosclerosis
Active Comparator group
Description:
coronary artery disease patients with carotid plaques confirmed by a ultrasound study
Treatment:
Other: 68Gallium-MSA
control
Sham Comparator group
Description:
no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
Treatment:
Other: 68Gallium-MSA

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems